Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - gliclazidum - retardtabletten - gliclazidum 60.00 mg, calcii hydrogenophosphas dihydricus, povidonum k 30, hypromellosum, magnesii stearas, excipiens pro compresso. - ipoglicemizzanti orali mezzi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - empagliflozinum, metformini hydrochloridum - compresse rivestite con film - empagliflozinum 12.5 mg metformini hydrochloridum 500 mg, per amylum pregelificatum, copovidonum, silice colloidalis anhydrica, magnesio stearas, Überzug: hypromellosum, macrogolum 400, e 171, e-172 (nero), e-172 (rosso), talco, pro compresso haze. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - empagliflozinum, metformini hydrochloridum - compresse rivestite con film - empagliflozinum 12.5 mg metformini hydrochloridum 850 mg per la amylum pregelificatum, copovidonum, silice colloidalis anhydrica, magnesio stearas, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (giallo) e 172 (rosso), talco, pro compresso haze. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - empagliflozinum, metformini hydrochloridum - compresse rivestite con film - empagliflozinum 12.5 mg metformini hydrochloridum 1000 mg, per amylum pregelificatum, copovidonum, silice colloidalis anhydrica, magnesio stearas, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (giallo) e 172 (rosso), talco, pro compresso haze. - antidiabetico - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

almus s.r.l. - metformina - metformina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

as grindeks - metformina e sitagliptina - metformina e sitagliptina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

adamed s.r.l. - metformina e sitagliptina - metformina e sitagliptina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bruno farmaceutici s.p.a. - metformina e sitagliptina - metformina e sitagliptina

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.